40 results about "Gynecomastia" patented technology

The present invention provides methods for treating and preventing gynecomastia by administering 4-hydroxy tamoxifen to a patient. When percutaneously administered to a patient's breasts, 4-hydroxy tamoxifen concentrates locally, and exerts an anti-estrogenic effect. In patients with gynecomastia, this reduces the effective estrogen-androgen ratio in the breast tissue, thereby reducing ductal proliferation, epithelial and stromal hyperplasia, and pain. In patients at risk for developing gynecomastia, 4-hydroxy tamoxifen's anti-estrogenic effect prevents tissue proliferation and its accompanying pain.

The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for treatment or prevention of a variety of conditions related to estrogen functioning including: bone loss, bone fractures, osteoporosis, cartilage degeneration, endometriosis, uterine fibroid disease, hot flashes, increased levels of LDL cholesterol, cardiovascular disease, impairment of cognitive functioning, cerebral degenerative disorders, restenosis, gynecomastia, vascular smooth muscle cell proliferation, obesity, incontinence, and cancer, in particular of the breast, uterus and prostate.

The present invention provides methods for reducing the incidence of, inhibiting, suppressing, reducing the incidence of, and treating androgen-deprivation induced osteoporosis, bone fractures and/or loss of bone mineral density (BMD) in men having prostate cancer, comprising administering to a male human subject having prostate cancer a toremifene and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof. The present invention also provides methods of treating, preventing, suppressing, inhibiting, or reducing the incidence of hot flashes, gynecomastia, and/or hair loss in male humans having prostate cancer, comprising same.

The present invention provides an external preparation of dihydrotestosterone. The preparation contains 0.01 percent to 5 percent of the dihydrotestosterone by weight percentage in a medicinal carrier of the preparation uniformly; wherein, the medicinal carrier is selected from solution, suspension, lotion, gel, ointment, cream, paste and patch. The preparation can remedy the primary, the secondary and the senile hypogonadism, the prostatic hyperplasia, the gynaecomastia and the lichen sclerosis et atrophicus. The medicated part can be arm, shoulder, inner thigh, chest, abdomen and genitalia.

A composition having modified or derivative of 1,4,6-androstatriene-3,17-dione (“ATD”) will improve the health of mammalian subjects. The improvement of health is achieved with the administration of an effective amount of the at least one modified or derivative of 1,4,6-androstatriene-3,17-dione. Particularly, health is improved for a subject suffering with a gynecomastia, and/or estrogen-dependent cancer. Also, subjects recovering from steroid misuse/abuse with treatment in accordance with the present invention. Other improvements found to occur with an administration of ATD is that growth is enhanced and/or stimulated in developing mammals, recovery is shortened in cases of severe trauma or burns, mood levels are improved, male fertility is improved, and athletic performance is improved by increasing testosterone and lean muscle mass.

The present invention relates to compounds and derivatives thereof, their cynthesis, and their use as estrogen receptor modulators. The compound of the instant invention are ligands for estrogen receptors and as such may be useful for treatment or prevention of a variety of conditions related to estrogen functioning including: bone loss, bone fractures, osteoporosis, cartilage degeneration, endometriosis, uterine fibroid desease, hot flashes, increased levels of LDL cholestterol, cardiovascular disease, impairment of cognitive functioning, cerebral degenerative disorders, restenosis, gynecomastia, vascular smooth muschle cell proliferation, obesity, incontinence, and cancer, in particular of the breast, uterus and prostate.

The present invention relates to methods for reducing testosterone levels in a male subject and methods of treating, suppressing, reducing the incidence, reducing the severity, or inhibiting prostate cancer, advanced prostate cancer, castration resistant prostate cancer (CRPC), metastatic castration resistant prostate cancer (mCRPC), and methods of reducing high or increasing PSA levels and/or increasing SHBG levels in a subject suffering from prostate cancer, advanced prostate cancer, castration resistant prostate cancer (CRPC) and metastatic castration resistant prostate cancer (mCRPC). The compounds of this invention suppress free or total testosterone levels despite castrate levels secondary to ADT and reduce high or increasing PSA levels. This reduction in testosterone levels may be used to treat prostate cancer, advanced prostate cancer, CRPC and mCRPC without causing bone loss, decreased bone mineral density, increased risk of bone fractures, increased body fat, hot flashes and/or gynecomastia.

The invention discloses a medicament for treating gynecomastia and a preparation method thereof. The medicament is mainly prepared from polygonum multiflorum, edible tulip, malt, herba epimedii, green tangerine peel, glossy privet fruit, oyster, Chinese yam and the like according to certain weight proportion. The medicament has the functions of clearing and activating the channels and collaterals, boosting essence, moistening dryness, removing heat from the liver, removing stasis, tonifying the kidney and tonifying Yang, is used for treating gynecomastia with a rapid effect, and is good in treatment effect and high in cure rate.

The invention relates to the field of medicinal chemistry and in particular relates to 4-imidazolyl quinoline and quinazoline ketone aromatizing enzyme inhibitors. The invention further discloses a preparation method and pharmacological activity of the inhibitors, a medicinal composition containing the compounds as well as the medical application of the inhibitors, in particular the medical application of the inhibitors in preventing or treating estrogen maintaining diseases such as breast cancers, endometrial cancers, female sexual precocity, gynecomastia and the like.

Methods for separation and synthesis of the optically active 7-thioester isomers and mono or bis-cyclopropyl derivatives of spironolactone are provided. Preferred stereoisomerically purified 7-thioester isomers and mono or bis-cyclopropyl derivatives of spironolactone have fewer effects mediated by gonadal steroid receptors relative to effect mediated by minteralocorticoid progesterone receptors, compared to the stereoisomerically unpurified form of the compound. These optically active compounds can be useful for obtaining reduction in moderate essential hypertension and it the treatment of congestive heart failure in humans with minimized undesirable side effects such as gynecomastia, tender breast enlargement and menstrual irregularities in women, and loss of libido in men.

The present invention discloses a Chinese medicine composition for effectively curing the diseases of cystic hyperplasia of breast, acute mastitis and fibroadenoma of breast, etc, with good therapeutic effect. Said Chinese medicine composition is made up by using 10 Chinese medicinal materials of Chinese angelica root, astragalus root, rhaponticum/echinops root, bupleurum root, curcuma tuber and others through a certain preparation process. Said invention also provides its preparation process and its quality control method.

The invention discloses a pill for treating gynecomastia and a preparation method thereof, and belongs to the field of traditional Chinese medicine. The pill comprises the raw materials of effective components: eucommia bark, radix dipsaci, semen cuscutae, white atractylodes rhizome, herba epimedii, fructus lycii, cortex cinnamomi, radix bupleuri, nutgrass galingale rhizome, pericarpium citri reticulatae, radix salviae miltiorrhizae, poria cocos, cortex moutan, rhizoma chuanxiong, radix paeoniae rubra, radix polygoni multiflori, rhizoma curcumae, cornua cervi pantotrichum, radix cyathulae, rhizoma alismatis, rhizoma pinellinae praeparata, tuber fleeceflower stem, bulbus fritillariae cirrhosae, licorice, pulp of cornus, and curculigo orchioides; the above medicines are processed in a certain way to prepare the pill product. The selected medicines meet the principle of different raw materials having different functions, drug properties are adapted and complemented with each other, the remedy is suited to the cases aiming at loss of nourishment of liver and kidney, blood and qi stagnation, liver qi depression and phlegm stasis, qi stagnation and blood stasis and other pathogenesis, and the pill has the effects of nourishing the liver and kidney, smoothing liver and resolving depression, and promoting blood circulation to remove meridian obstruction, has the advantages of good absorption effect, obvious curative effect, no toxic or side effect and no clinical adverse reactions, and has relatively high cure rate on gynecomastia through clinical verification.

A method and composition for the treatment of prostate cancer comprises an effective amount of a nonsteroidal antiandrogen and an effective amount of a selective estrogen receptor modulator. The composition has fewer side effects such as breast tenderness and gynecomastia and also is more effective as an adjuvant therapy to prevent the reoccurrence of prostate cancer.

The invention discloses a Chinese medicinal herb formula for treating gynecomastism, which is characterized by consisting of the following Chinese medicinal herbs by weight: 20 grams of root of red rooted salvia, 20 grams of malt, 15 grams of white paeony root, 15 grams of tuber of multiflower knotweed, 15 grams of Chinese yam rhizome, 10 grams of Chinese angelica, 10 grams of pilose asiabell root, 10 grams of nutgrass galingale rhizome, 15 grams of glossy privet fruit, 8 grams of root of rehmannia and 8 grams of prepared root of rehmannia. The Chinese medicinal herbs are decocted by using water. The method is simple and feasible, and a patient can implement the method at home; and the prepared medicament has low cost and has good healing effect on the gynecomastism. The gynecomastism can be totally healed after the medicament is administrated for three courses at most.

The present invention relates to methods for reducing testosterone levels in a male subject and methods of treating, suppressing, reducing the incidence, reducing the severity, or inhibiting prostate cancer, advanced prostate cancer, castration resistant prostate cancer (CRPC), metastatic castration resistant prostate cancer (mCRPC), and methods of reducing high or increasing PSA levels and/or increasing SHBG levels in a subject suffering from prostate cancer, advanced prostate cancer, castration resistant prostate cancer (CRPC) and metastatic castration resistant prostate cancer (mCRPC). The compounds of this invention suppress free or total testosterone levels despite castrate levels secondary to ADT and reduce high or increasing PSA levels. This reduction in testosterone levels may be used to treat prostate cancer, advanced prostate cancer, CRPC and mCRPC without causing bone loss, decreased bone mineral density, increased risk of bone fractures, increased body fat, hot flashes and/or gynecomastia.

The mastoproliferation treating Chinese medicine is prepared with ten kinds of Chinese medicinal materials including epimedium, astragalus root, bupleurum root, angelica, curcuma root, kelp, etc. The Chinese medicine of the present invention has the functions of soothing the liver, alleviating mental depression, softening the dry feces, dissipating mass, regulating vital energy and promoting blood circulation, and is used in treating acute mastitis, mastoproliferation, fibroadenoma of breast, male's mammary development and other diseases.

The invention relates to a traditional Chinese medicine composition for treating gynecomastia. The traditional Chinese medicine composition comprises, by weight, 10-30 parts of scutellariae barbatae, 5-20 parts of melia toosendan, 5-25 parts of cynomorium songaricum, 10-30 parts of rhizoma pleionis, 5-20 parts of medical pipefish, 5-25 parts of concha meretricis seu cyclinae, 5-25 parts of mentha haplocalyx, 5-20 parts of rhizoma chuanxiong, 10-30 parts of radix acanthopanacis senticosi, 5-20 parts of botrypus virginianus, 5-25 parts of taraxacum mongolicum, 5-25 parts of rhizoma bolbostemmae, 5-25 parts of semen astragali complanati, 5-20 parts of rhizoma cyperi, 5-25 parts of concha arcae, 5-25 parts of semen cuscutae, 5-20 parts of radix ranunculi ternati, 5-25 parts of caulis polygoni multiflora, 5-25 parts of carthamus tinctorious, 5-25 parts of radix curcuma, 5-20 parts of prepared polygonum multiflorum, 5-25 parts of polygonum cuspidatum and 5-15 parts of radix glycyrrhizae. The traditional Chinese medicine composition has effects of tonifying the liver and kidney, soothing the liver and expelling heat, reducing phlegm and softening hard mass, eliminating stagnation and diminishing swelling, promoting qi circulation and relieving depression, and clearing the channels and collaterals and relieving pain and is evident and reliable in curative effect on the gynecomastia.